Certified by Founder Lodge
CellCentric
United Kingdom - Cambridge
START UP
1 Disclosed Funding Rounds $25,000,000
0 Participating Investments
-
Founded date
2004
-
Operating Status
Active
-
Last Funding Type
Seed
-
Company Type
For Profit
- Website
- Contact
- Social Links
Inobrodib is the first small molecule drug in the clinic targeting twin proteins p300 and CBP. It is formulated as a capsule taken orally.
p300/CBP are twin (paralogue) acetyl transferases
Pfizer
IDRx
CAMP4 Therapeutics
Delfi Diagnostics
xilis
Manifold Bio
TG0 | $5,619,170 | (Dec 20, 2024)
Double(US) | $3,900,000 | (Dec 20, 2024)
Mindgard | $8,000,000 | (Dec 20, 2024)
Hauler Hero | $10,000,000 | (Dec 20, 2024)
LeapFinancial | $3,500,000 | (Dec 20, 2024)
